Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.98 AUD | -1.24% | +0.93% | -2.04% |
Apr. 30 | Evotec, Bayer to Focus on Precision Treatments for Cardiovascular Diseases | MT |
Apr. 24 | Germany's Evotec Appoints Permanent CEO | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 75.39 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Leisure & Recreation
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.04% | 1.29B | C | ||
+6.68% | 4.19B | D+ | ||
+23.28% | 2.08B | C | ||
-.--% | 1.73B | - | ||
-21.65% | 1.56B | C+ | ||
-10.18% | 1.16B | C- | ||
-18.52% | 1.14B | - | ||
-47.88% | 882M | D | ||
-.--% | 818M | - | - | |
+0.87% | 523M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EVT Stock
- Ratings EVT Limited